Table 1 Suggested data collection form completed with data extracted from the report of the example trial in bladder cancer [6]
From: Practical methods for incorporating summary time-to-event data into meta-analysis
Trial Reference: BA06 | (Chemotherapy) | (No chemotherapy) |
|---|---|---|
Randomisation ratio (e.g. 1:1) | 1 | 1 |
Patients randomised | 491 | 485 |
Patients analysed | 491 | 485 |
Observed events | 229 | 256 |
Logrank expected events | Not reported | Not reported |
Hazard ratio, confidence interval (& level e.g. 95%) | 0.85, CI 0.71 to1.02 (95%) | |
Logrank variance | Not reported | |
Logrank observed minus-expected events | Not reported | |
Hazard ratio and confidence interval (& level e.g. 95%) or standard error or variance from adjusted or unadjusted Cox | Not reported | |
Test statistic, 2-sided p-value to 2 significant figures (& test used e.g. logrank, Mantel-Haenzsel or Cox) | Not reported, 0.075 (logrank) | |
Advantage to research or control? | Research | |
Actuarial or Kaplan Meier curves reported? | Yes, Kaplan Meier | |
Numbers at risk reported | Yes | |
Follow-up details | Min = 14 months, Max = 82 months (Estimated from recruitment of 69 months, 11/9 – 7/95 and median follow-up of 48 months) | |